Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETAIN: Ranibizumab Treat-and-Extend in Diabetic Macular Edema
NCT01171976Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2010
- Primary completion
- Apr 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12. Started Sep 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01171976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171976.